Skip to main content

Table 5 Mean increase in scores from baseline to 90 day in the KyberSept Trial by subgroups: all-survivors

From: Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]

  Mobility Physical activity Communications/speech Level of alertness Energy level Overall QoL Karnofsky
Parameter Placebo AT III Placebo AT III Placebo AT III Placebo AT III Placebo AT III Placebo AT III Placebo AT III
SAPS II risk               
   Moderate 49 ± 23 51 ± 24 48 ± 22 50 ± 23 43 ± 35 48 ± 33 43 ± 34 47 ± 33 47 ± 22 49 ± 22 50 ± 23 50 ± 21 49 ± 18 49 ± 18
   High 51 ± 24 52 ± 23 50 ± 22 51 ± 22 58 ± 31 61 ± 30 56 ± 28 60 ± 29 48 ± 23 51 ± 22 53 ± 22   54 ± 23 44 ± 19 46 ± 19
   Very high 47 ± 26 52 ± 26 44 ± 25 50 ± 25 59 ± 35 66 ± 29 59 ± 33 67 ± 28 46 ± 23 51 ± 24 50 ± 25 55 ± 25 41 ± 21 43 ± 19
Admitting diagnosis               
   Respiratory 50 ± 25 54 ± 23 48 ± 23 52 ± 23 51 ± 35 59 ± 33 52 ± 32 58 ± 32 46 ± 23 51 ± 22 52 ± 24 55 ± 22 46 ± 19 49 ± 18
   Digestive 50 ± 23 52 ± 24 49 ± 23 50 ± 23 55 ± 35 60 ± 31 54 ± 33 59 ± 31 46 ± 24 49 ± 22 52 ± 23 51 ± 24 45 ± 19 46 ± 19
   Genitourinary 46 ± 21 43 ± 26 46 ± 20 43 ± 25 40 ± 36 40 ± 34 40 ± 34 37 ± 34 49 ± 19 44 ± 22 48 ± 21 44 ± 25 47 ± 20 45 ± 18
   Injury 51 ± 24 47 ± 27 52 ± 22 48 ± 26 58 ± 26 55 ± 29 55 ± 27 59 ± 29 49 ± 21 52 ± 26 53 ± 18 53 ± 24 67 ± 21 70 ± 19
   Other 48 ± 25 51 ± 24 48 ± 23 51 ± 23 53 ± 33 56 ± 31 52 ± 30 56 ± 31 48 ± 23 53 ± 22 51 ± 24 54 ± 21 69 ± 21 68 ± 18
Concomitant heparin               
   No 44 ± 22 48 ± 24 43 ± 21 48 ± 22* 42 ± 36 51 ± 31 42 ± 33 49 ± 31 43 ± 22 49 ± 22 47 ± 22 51 ± 23 43 ± 19 43 ± 19
   Yes 51 ± 24 53 ± 24 50 ± 23 52 ± 24 55 ± 33 60 ± 32 54 ± 31 59 ± 31* 48 ± 23 52 ± 22 52 ± 23 54 ± 23 46 ± 19 46 ± 19
  1. Values are expressed as mean ± SD. *P < 0.05 versus placebo; P < 0.1 versus placebo. Mean scores represent changes between the 90-day and the baseline values for all-survivors (those in hospital 90 days from study enrollment, or closest time point to 90 days [last observation carried forward analysis; see text]). All mean scores increased (higher scores indicate better quality of life [QoL]). AT, antithrombin.